What is Chardan Capital’s Forecast for PRAX FY2025 Earnings?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Investment analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Praxis Precision Medicines in a research report issued to clients and investors on Tuesday, May 13th. Chardan Capital analyst R. Li anticipates that the company will post earnings per share of ($11.25) for the year. Chardan Capital currently has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. Chardan Capital also issued estimates for Praxis Precision Medicines’ FY2026 earnings at ($3.70) EPS.

Praxis Precision Medicines (NASDAQ:PRAX) last released its earnings results on Friday, May 2nd. The company reported ($3.29) EPS for the quarter, missing the consensus estimate of ($3.20) by ($0.09). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%.

A number of other equities research analysts have also issued reports on PRAX. Needham & Company LLC reissued a “buy” rating and issued a $80.00 price target on shares of Praxis Precision Medicines in a report on Monday, May 5th. Robert W. Baird cut their price target on shares of Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Deutsche Bank Aktiengesellschaft began coverage on shares of Praxis Precision Medicines in a report on Tuesday, February 11th. They issued a “buy” rating and a $111.00 price target on the stock. Wedbush raised their price target on shares of Praxis Precision Medicines from $26.00 to $28.00 and gave the stock an “underperform” rating in a report on Monday, May 5th. Finally, Truist Financial cut their price target on shares of Praxis Precision Medicines from $175.00 to $85.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, Praxis Precision Medicines currently has an average rating of “Moderate Buy” and a consensus price target of $116.50.

Praxis Precision Medicines Stock Performance

PRAX stock opened at $37.02 on Friday. Praxis Precision Medicines has a 52 week low of $26.70 and a 52 week high of $91.83. The firm’s fifty day moving average is $35.60 and its 200 day moving average is $59.67. The firm has a market cap of $754.06 million, a P/E ratio of -3.59 and a beta of 2.65.

Institutional Investors Weigh In On Praxis Precision Medicines

Several institutional investors and hedge funds have recently modified their holdings of PRAX. Adage Capital Partners GP L.L.C. lifted its position in shares of Praxis Precision Medicines by 188.1% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,742,758 shares of the company’s stock worth $65,998,000 after purchasing an additional 1,137,748 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Praxis Precision Medicines by 5,437.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 559,082 shares of the company’s stock worth $43,027,000 after purchasing an additional 548,986 shares during the period. Janus Henderson Group PLC lifted its position in shares of Praxis Precision Medicines by 77.5% in the 4th quarter. Janus Henderson Group PLC now owns 929,523 shares of the company’s stock worth $71,621,000 after purchasing an additional 405,957 shares during the period. Driehaus Capital Management LLC lifted its position in Praxis Precision Medicines by 192.0% during the 1st quarter. Driehaus Capital Management LLC now owns 481,598 shares of the company’s stock valued at $18,238,000 after acquiring an additional 316,686 shares during the period. Finally, VR Adviser LLC lifted its position in Praxis Precision Medicines by 40.2% during the 4th quarter. VR Adviser LLC now owns 989,985 shares of the company’s stock valued at $76,189,000 after acquiring an additional 283,854 shares during the period. 67.84% of the stock is owned by hedge funds and other institutional investors.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.